MRI Dye Technique Could Detect HIV Dementia
By MedImaging International staff writers Posted on 07 Mar 2016 |
Image: MRI of the brain before (A) and after (B) ferumoxytol injection. A magnified image (C) demonstrates ferumoxytol accumulation (Photo courtesy of the University of Hawaii).
A new magnetic resonant imaging (MRI) contrast dye could be used to target specific white blood cells (WBCs) believed to play a key role in the development of HIV-associated neurocognitive disorders (HAND).
Researchers at the University of Hawaii (Honolulu, USA) are conducting studies to examine the use of ferumoxytol—an ultra-small iron oxide MRI contrast agent—to identify and quantitate monocyte/macrophage (M/MΦ)-mediated inflammation in the brain of HIV-infected people. M/MΦs are believed to play a critical role in the pathogenesis of HAND, but neuroimaging HIV research has not as yet focused on assessing M/MΦ-mediated inflammation in the brain, since no modality exists that can define inflammation extent as a diagnostic tool, or assist in defining objective improvement in clinical trials addressing HAND.
The researchers hypothesized that imaging based on ferumoxytol, which is avidly taken up by circulating M/MΦs, could identify ongoing inflammation resulting from the perivascular M/MΦ, a key pathologic correlate of HAND. The neurocognitive disorders in HIV continue to be prevalent, despite effective combination antiretroviral therapy (cART), and are responsible for a significant impact on morbidity and quality of life. The researchers believe that once M/MΦs have switched on to battle HIV, an unintended consequence is the production of toxic chemicals in the brain that cause uncontrolled inflammation and ultimately cognitive impairment.
“Four HIV-infected subjects with undetectable HIV RNA levels on antiretroviral therapy and cognitive impairment underwent ferumoxtyol-enhanced brain MRI,” wrote lead investigator Neurologist Beau Nakamoto, MD, PhD, in a 2013 study. “On post-ferumoxytol susceptibility-weighted images, all HIV-infected subjects demonstrated a diffuse “tram track” appearance in the perivascular regions of cortical and deep white matter vessels, suggesting ferumoxytol uptake in monocytes/macrophages. This finding was not present in a HIV-seronegative control.”
Related Links:
University of Hawaii
Researchers at the University of Hawaii (Honolulu, USA) are conducting studies to examine the use of ferumoxytol—an ultra-small iron oxide MRI contrast agent—to identify and quantitate monocyte/macrophage (M/MΦ)-mediated inflammation in the brain of HIV-infected people. M/MΦs are believed to play a critical role in the pathogenesis of HAND, but neuroimaging HIV research has not as yet focused on assessing M/MΦ-mediated inflammation in the brain, since no modality exists that can define inflammation extent as a diagnostic tool, or assist in defining objective improvement in clinical trials addressing HAND.
The researchers hypothesized that imaging based on ferumoxytol, which is avidly taken up by circulating M/MΦs, could identify ongoing inflammation resulting from the perivascular M/MΦ, a key pathologic correlate of HAND. The neurocognitive disorders in HIV continue to be prevalent, despite effective combination antiretroviral therapy (cART), and are responsible for a significant impact on morbidity and quality of life. The researchers believe that once M/MΦs have switched on to battle HIV, an unintended consequence is the production of toxic chemicals in the brain that cause uncontrolled inflammation and ultimately cognitive impairment.
“Four HIV-infected subjects with undetectable HIV RNA levels on antiretroviral therapy and cognitive impairment underwent ferumoxtyol-enhanced brain MRI,” wrote lead investigator Neurologist Beau Nakamoto, MD, PhD, in a 2013 study. “On post-ferumoxytol susceptibility-weighted images, all HIV-infected subjects demonstrated a diffuse “tram track” appearance in the perivascular regions of cortical and deep white matter vessels, suggesting ferumoxytol uptake in monocytes/macrophages. This finding was not present in a HIV-seronegative control.”
Related Links:
University of Hawaii
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer